Tips for Therapeutics to Ensure Biotechnologies Antisense RNAi

1
PharmaSphere Emerging Biotechnologies - Antisense
RNAi Therapeutics Market Analysis
Telephone [phone]Mail at
sales_at_researchbeam.com
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
Published on Oct 2014
2


Report Overview

• Summary
• Emerging Biotechnologies Antisense RNAi
  Therapeutics Market Analysis report is an
  essential source of information and analysis on
  the RNA interference (RNAi) therapy field. Using
  detailed company data, deal analysis, corporate
  strategy, and market trends, It provides an
  in-depth analysis of the current and future
  growth drivers of the RNAi therapy market. The
  report discusses the key factors shaping and
  driving the RNAi therapy business, and provides
  insights into the competitive landscape and
  emerging strategies expected to significantly
  influence the market positions of companies
  currently involved in the development and
  commercialization of RNAi therapeutics.
• Highlights
• Key Questions Answered
• What are the drivers of the RNAi therapy field?
• Who are the leading companies involved in the
  development of RNAi therapies?
• What are the major trends in RNAi clinical
  trials?
• What specific therapeutic areas and indications
  are receiving the most clinical research?
• What specific business development activities are
  taking place in terms of partnerships or mergers
  and acquisitions (MAs)?
• Has investor confidence been restored in the
  antisense/RNAi therapy field?

3


Report Overview

• Scope
• This report provides market developments across
  the RNAi therapy field, including clinical
  trials, deals, and pipeline investments
• Investment examined from both industry and
  financial communities
• Clinical trials activity examined across phase of
  development, therapy area, and indication.
• This report offers a deep dive into the synergies
  behind partnering and acquisition activities
• Deals examined across geography, entity type,
  company, financial advisor, phase of development,
  therapy area, indication, and mechanism of action
• Pipeline profiles of 25 leading biotech companies
  developing RNAi therapeutics
• Reasons to buy
• Identify the key players in the RNAi market.
• Analyze and track the strategies that companies
  are using to strengthen their position in the
  RNAi therapy field independent source for due
  diligence.
• Organize your sales and marketing strategy to
  identify companies with proprietary technologies
  in order to maximize opportunities for licensing,
  partnership, investment, or takeover.
• Understand the flow of investment from capital
  markets into the RNAi therapy field.

4


Table of Contents
1 Table of Contents 6 1.1 List of Tables 9 1.2
List of Figures 11 2 Introduction 13 2.1 Report
Scope 13 2.2 Companies Mentioned 14 2.3 Related
Reports 14 3 Antisense RNAi Therapy Overview
15 3.1 What is Antisense Therapy? 15 3.2 The
Second Era of RNAi 17 4 Clinical Trials 19 4.1
Overview 19 4.2 Company 20 4.3 Phase of
Development 22 5 Company Analysis 36 5.1 Overview
36 5.2 Pipeline Profiles 39 6 Deals Landscape
886.1 Overview 886.1.1 Geography 89 6.2 Deal
Type 103 7 Strategic Outlook 119
5


List of Tables
Table 1 Alnylam Pharmaceuticals, Pipeline
Programs, Phase I-III 41 Table 2 Alnylam
Pharmaceuticals, Pipeline Programs, Preclinical
43 Table 3 Alnylam Pharmaceuticals, Pipeline
Programs, Discovery 44 Table 4 Antisense
Therapeutics 46 Table 5 Arrowhead Research
Corporation 48 Table 6 AuraSense Therapeutics
50 Table 7 BioMarin Pharmaceuticals 52 Table 8
Dicerna Pharmaceuticals 54 Table 9 Gene Signal
International SA 56 Table 10 Idera
Pharmaceuticals 57 Table 11 InDex
Pharmaceuticals AB 59 Table 12 Isarna
Therapeutics GmbH 60 Table 13 Isis
Pharmaceuticals, Pipeline Programs, Phase II-III
62 Table 14 Isis Pharmaceuticals, Pipeline
Programs, Phase I 63 Table 15 Isis
Pharmaceuticals, Pipeline Programs, Preclinical
64 Table 16 Miragen Therapeutics 66 Table 17
Mirna Therapeutics 67 Table 18 Moderna
Therapeutics 68 Table 19 Mologen AG 70 Table 20
Oncogenex Pharmaceuticals 72 Table 21 Quark
Pharmaceuticals 73 Table 22 Regulus Therapeutics
74 Table 23 RXi Pharmaceuticals 76
6


Report Ordering
Report Name PharmaSphere Emerging
Biotechnologies - Antisense RNAi
Therapeutics Market Analysis
Product Price
User Price
Single User US 2546
Site User US 5990
Global User US 8985
To View Sample or Purchase Report
7



Contact Us
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/pharmasphere-emerging-
biotechnologies-antisense-rnai-therapeutics-analys
is-market
Stay With Us At
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] DIRECT 1 (503)
894-6022E-MAIL sales_at_researchbeam.com